09/08/2016
https://congress.gov...
"When a company delays the start of the exclusivity period of a product, it not only delays other generics from coming to market, it also delays lower prices reaching patients sooner."
"The bills we are considering today will inject competition in the system sooner, move drugs to the market more quickly, and lower costs."
"We know that when generics come to market, they can drive prices down exponentially for consumers."
"When brand and generic manufacturers employ these tactics, it is really the American people that lose out."